2079895-62-6
Chemical Structure
TP-472
- CAS No.: 2079895-62-6
- Formula:C20H19N3O2
- Molecular Weight:333.38
IUPAC Name: 3-(6-acetylpyrrolo[1,2-a]pyrimidin-8-yl)-N-cyclopropyl-4-methylbenzamide
InChIKey: RPBMXJHQYJLPDN-UHFFFAOYSA-N
SMILES: O=C(C)C1=CC(C2=C(C)C=CC(C(NC3CC3)=O)=C2)=C4N=CC=CN41
Biological Activity: TP-472, a chemical probe, is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7[1][2]. TP-472 induces apoptosis of melanoma cells[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TP-472 | 99.54% | TP-472, a chemical probe, is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7. TP-472 induces apoptosis of melanoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TP-472 (Standard) | ≥98% | TP-472 (Standard) is the analytical standard of TP-472 (HY-100517). This product is intended for research and analytical applications. TP-472, a chemical probe, is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7. TP-472 induces apoptosis of melanoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Moustakim M, et al. Chemical probes and inhibitors of bromodomains outside the BET family. Medchemcomm. 2016 Dec 7;7(12):2246-2264. [Content Brief]
- [2]. Gatchalian J, et al. A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. Nat Commun. 2018 Dec 3;9(1):5139. [Content Brief]
- [3]. Lawrence David Mason, et al. The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis. Cancers (Basel). 2021 Nov 3;13(21):5516. [Content Brief]
Keywords